ImpediMed on publication of new SOZO data

Latest News

ImpediMed (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate patient data, has announced the publication of a peer-reviewed manuscript demonstrating the clinical utility of its SOZO device in monitoring heart failure patients.

The publication in Frontiers in Cardiovascular Medicine is titled 'Clinical Utility of Fluid Volume Assessment in Heart Failure Patients Using Bioimpedance Spectroscopy'.

It describes the BIS-derived HF-DexTM values, Extracellular Fluid expressed as a percentage of Total Body Water (ECF%TBW), in a clinically relevant way that the company said can be used by physicians to aid in clinical risk stratification and fluid volume monitoring of heart failure patients.

“While BIS technology has been validated for fluid monitoring, the lack of established reference ranges in heart failure has limited its effectiveness for workflow implementation. The current study illustrates the use of a HF-Dex scale differentiating normal from abnormal extracellular fluid. Identifying subclinical fluid overload would be valuable in risk factor stratification for heart failure patients in the acute and chronic settings,” said Dr Andrew Accardi, emergency medicine physician at Scripps Health in San Diego and first author of the manuscript.

“The use of HF-Dex in BIS shows promise to monitor and follow volume status in heart failure. While the current technology has been in use for lymphoedema, the present study illustrates the potential utility as a tool to aid in clinical decision making for heart failure patients,” said Dr Tom Heywood, medical director, Advanced Heart Failure and Mechanical Circulatory Support Program at Scripps Health and senior author of the manuscript.

“We are very pleased with the progress made in Heart Failure through this study and our continued collaboration with Scripps Health. This study is a critical step in obtaining real world evidence for our HF-Dex application. It demonstrates that SOZO can track patient fluid levels and that established normative range data can be useful in risk stratifying patients,” added Richard Carreon, managing director and CEO of ImpediMed.